NTCELL for Parkinson’s disease shows promising results on efficacy and safety in Ph II trials

As per Living Cell Technologies, the one year follow up of the 18 patients in the Phase IIb study of NTCELL® for Parkinson’s disease has shown a statistically significant improvement change in the Unified Parkinson’s Disease Rating Scale (UPDRS Part III in the off state) in the patients who received 40 or 80 NTCELL capsules implantation to the putamen on both sides of the brain as compared to the placebo group that received sham surgery. The Data Safety Monitoring Board has advised that there are no safety issues arising from the data.

The study was designed to confirm the most effective dose of NTCELL, define any placebo component of the response and further identify the initial target Parkinson’s disease patient sub group. The study consisted of three groups of six patients. Two patients from each group had sham surgery with no NTCELL implanted, to act as a control. Group 1 received 40 microcapsules of NTCELL implanted on each side of the brain; group 2 received 80; and group 3 received 120.

The principal investigator, Dr Barry Snow, Auckland City Hospital, said, “The treatment is safe. There are clinical signals of interest. We need to continue to monitor patients for longer to examine the clinical significance of this efficacy data.”

Dr Ken Taylor, CEO of LCT, said, “We are encouraged to see efficacy data at the longer time point. We need to further analyse this encouraging result at future time points to assess NTCELL as a potential treatment for Parkinson’s disease.”

About Pharmascroll:

Pharmascroll is a diligent business consulting and market research firm focused solely towards pharmaceutical markets. The company consults and researches in majorly chronic disease indications prevalent across the globe. The research conducted by Pharmascroll analysts is targeted to provide analytical and logical answers to the key business questions of the pharmaceutical and medical insights teams and to make better informed business decisions with the detailed relevant information available.

To read more news about Parkinson’s disease indication, visit https://pharmascroll.com/news-category/parkinsons/

News Source: Living Cell Technologies website